Novel Antagonists of Heparin Binding Growth Factors

por Cecchi, Fabiola, Bottaro, Donald P.
Publicado 2012

Stable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK Cells

por Chu, Chia, Bottaro, Donald P., Betenbaugh, Michael J., Shiloach, Joseph
Publicado 2016

Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder

por Lee, Young H., Apolo, Andrea B., Agarwal, Piyush K., Bottaro, Donald P.
Publicado 2014

Heparin Inhibits Hepatocyte Growth Factor Induced Motility and Invasion of Hepatocellular Carcinoma Cells through Early Growth Response Protein 1

por Ozen, Evin, Gozukizil, Aysim, Erdal, Esra, Uren, Aykut, Bottaro, Donald P., Atabey, Nese
Publicado 2012

Hepatocyte growth factor/MET in cancer progression and biomarker discovery

por Matsumoto, Kunio, Umitsu, Masataka, De Silva, Dinuka M., Roy, Arpita, Bottaro, Donald P.
Publicado 2017

Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist

por Zhang, Manchao, Luo, Zhenghua, Liu, Hongpeng, Croce, Carlo M., Burke, Terrence R., Bottaro, Donald P.
Publicado 2013

MET Inhibition in Clear Cell Renal Cell Carcinoma

por Xie, Zuoquan, Lee, Young H., Boeke, Marta, Jilaveanu, Lucia B., Liu, Zongzhi, Bottaro, Donald P., Kluger, Harriet M., Shuch, Brian
Publicado 2016

Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer

por Kaye, Deborah R., Pinto, Peter A., Cecchi, Fabiola, Reilly, Joseph, Semerjian, Alice, Rabe, Daniel C., Gupta, Gopal, Choyke, Peter L., Bottaro, Donald P.
Publicado 2016

Regression of Human Breast Carcinoma in Nude Mice after Adsflt Gene Therapy Is Mediated by Tumor Vascular Endothelial Cell Apoptosis

por Felici, Angelina, Bottaro, Donald P., Mangoni, Antonella, Reusch, Petra, Marmé, Dieter, Kovesdi, Imre, De Silva, Dinuka M., Lee, Young H., Capogrossi, Maurizio C., Mühlhauser, Judith
Publicado 2022

Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling

por Cecchi, Fabiola, Rex, Karen, Schmidt, Joanna, Vocke, Cathy D., Lee, Young H., Burkett, Sandra, Baker, Daniel, Damore, Michael A., Coxon, Angela, Burgess, Teresa L., Bottaro, Donald P.
Publicado 2023

Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder

por Lee, Young H., Lee, Molly M., De Silva, Dinuka M., Roy, Arpita, Wright, Cara E., Wong, Tiffany K., Costello, Rene, Olaku, Oluwole, Grubb, Robert L., Agarwal, Piyush K., Apolo, Andrea B., Bottaro, Donald P.
Publicado 2021

Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma

por Pahwa, Roma, Dubhashi, Janhavi, Singh, Anand, Jailwala, Parthav, Lobanov, Alexei, Thomas, Craig J., Ceribelli, Michele, Wilson, Kelli, Ricketts, Christopher J., Vocke, Cathy D., Wells, Catherine, Bottaro, Donald P., Linehan, W. Marston, Neckers, Len, Srinivasan, Ramaprasad
Publicado 2022

Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder

por McNeil, Brian K, Sorbellini, Maximiliano, Grubb, Robert L, Apolo, Andrea, Cecchi, Fabiola, Athauda, Gagani, Cohen, Benjamin, Giubellino, Alessio, Simpson, Haley, Agarwal, Piyush K, Coleman, Jonathan, Getzenberg, Robert H, Netto, George J, Shih, Joanna, Linehan, W Marston, Pinto, Peter A, Bottaro, Donald P
Publicado 2014

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors

por Kummar, Shivaani, Srivastava, Apurva K., Navas, Tony, Cecchi, Fabiola, Lee, Young H., Bottaro, Donald P., Park, Sook Ryun, Do, Khanh T., Jeong, Woondong, Johnson, Barry C., Voth, Andrea R., Rubinstein, Larry, Wright, John J., Parchment, Ralph E., Doroshow, James H., Chen, Alice P.
Publicado 2021

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

por Shah, Manish A., Wainberg, Zev A., Catenacci, Daniel V. T., Hochster, Howard S., Ford, James, Kunz, Pamela, Lee, Fa-Chyi, Kallender, Howard, Cecchi, Fabiola, Rabe, Daniel C., Keer, Harold, Martin, Anne-Marie, Liu, Yuan, Gagnon, Robert, Bonate, Peter, Liu, Li, Gilmer, Tona, Bottaro, Donald P.
Publicado 2021

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

por Shah, Manish A., Wainberg, Zev A., Catenacci, Daniel V. T., Hochster, Howard S., Ford, James, Kunz, Pamela, Lee, Fa-Chyi, Kallender, Howard, Cecchi, Fabiola, Rabe, Daniel C., Keer, Harold, Martin, Anne-Marie, Liu, Yuan, Gagnon, Robert, Bonate, Peter, Liu, Li, Gilmer, Tona, Bottaro, Donald P.
Publicado 2022

Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue

por Catenacci, Daniel V. T., Liao, Wei-Li, Thyparambil, Sheeno, Henderson, Les, Xu, Peng, Zhao, Lei, Rambo, Brittany, Hart, John, Xiao, Shu-Yuan, Bengali, Kathleen, Uzzell, Jamar, Darfler, Marlene, Krizman, David B., Cecchi, Fabiola, Bottaro, Donald P., Karrison, Theodore, Veenstra, Timothy D., Hembrough, Todd, Burrows, Jon
Publicado 2014

Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells

por Navas, Tony, Pfister, Thomas D., Colantonio, Simona, Aziz, Amina, Dieckman, Lynda, Saul, Richard G., Kaczmarczyk, Jan, Borgel, Suzanne, Alcoser, Sergio Y., Hollingshead, Melinda G., Lee, Young H., Bottaro, Donald P., Hiltke, Tara, Whiteley, Gordon, Takebe, Naoko, Kinders, Robert J., Parchment, Ralph E., Tomaszewski, Joseph E., Doroshow, James H.
Publicado 2018

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

por Girardi, Daniel M., Niglio, Scot A., Mortazavi, Amir, Nadal, Rosa, Lara, Primo, Pal, Sumanta K., Saraiya, Biren, Cordes, Lisa, Ley, Lisa, Ortiz, Olena Sierra, Cadena, Jacqueline, Diaz, Carlos, Bagheri, Hadi, Redd, Bernadette, Steinberg, Seth M., Costello, Rene, Chan, Keith S., Lee, Min-Jung, Lee, Sunmin, Yu, Yunkai, Gurram, Sandeep, Chalfin, Heather J., Valera, Vladimir, Figg, William D., Merino, Maria, Toubaji, Antoun, Streicher, Howard, Wright, John J., Sharon, Elad, Parnes, Howard L., Ning, Yang-Min, Bottaro, Donald P., Cao, Liang, Trepel, Jane B., Apolo, Andrea B.
Publicado 2022

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

por Apolo, Andrea B., Nadal, Rosa, Girardi, Daniel M., Niglio, Scot A., Ley, Lisa, Cordes, Lisa M., Steinberg, Seth M., Sierra Ortiz, Olena, Cadena, Jacqueline, Diaz, Carlos, Mallek, Marissa, Davarpanah, Nicole N., Costello, Rene, Trepel, Jane B., Lee, Min-Jung, Merino, Maria J., Bagheri, Mohammad Hadi, Monk, Paul, Figg, William D., Gulley, James L., Agarwal, Piyush K., Valera, Vladimir, Chalfin, Heather J., Jones, Jennifer, Streicher, Howard, Wright, John J., Ning, Yangmin M., Parnes, Howard L., Dahut, William L., Bottaro, Donald P., Lara, Primo N., Saraiya, Biren, Pal, Sumanta K., Stein, Mark N., Mortazavi, Amir
Publicado 2020